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ABSTRACT 
 
This review aims to enlighten the readers regarding the past, present and future of stem cells in the 
treatment of Diabetes. Diabetes is one of the leading causes of morbidity and mortality, affecting 
more than 415 million people worldwide.  It is estimated that one in ten adults will have diabetes by 
2030. Diabetes is mainly due to reduction in β-cell mass which are responsible for insulin 
production. Exogenous administration of insulin is having good impact on restoring glucose 
homeostasis, but it does not entirely control the minute-to-minute fluctuations in systemic blood 
glucose. Recently cellular-based therapies have been established for exogenous insulin 
administration by modern pump technology. One of the most interesting therapies involves 
substitution of insulin producing islet cells by transplantation. But lack of donor material and lifelong 
immunosuppression made the technique unfeasible. These restrictions have led to exploration of 
other sources of β-cells, one of the prospects being the stem cells. Several types of stem cells have 
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been used to make pancreatic β-cells, including human embryonic stem cells / induced pluripotent 
stem cells, pancreatic stem / progenitor cells, and non-pancreatic stem cells. There is also evidence 
of adult β-cells regeneration through β-cell replication and cellular reprogramming. Functional 
restoration of existing β-cells, transplantation of stem cells or stem cell-derived β-like cells might 
provide new opportunities for treatment. In conclusion it can be said that the research is still wide 
open to arrive at the efficient reprogramming of various types of stem cells to destine them towards 
functional β-cells. 
 
 
Keywords: Diabetes Mellitus; β-cell of pancreas; stem cell therapy; pluripotent stem cells; 
differentiation. 
 
1. INTRODUCTION  
 
Diabetes mellitus is a metabolic disorder 
characterized by uncontrolled high blood glucose 
levels. It is considered as global epidemic with 
continuous increase in its prevalence and 
incidence worldwide [1, 2]. Diabetes currently 
affects 8.5% of the world’s population – nearly 
415 million individuals worldwide. The World 
Health Organization predicts that diabetes 
deaths will double between 2015 and 2030 [3]. 
The statistical data on the incidence of diabetes 
in India is tabulated below. The major forms of 
the disease are Type 1 (Insulin-Dependent 
Diabetes Mellitus) and Type 2 diabetes (Non-
Insulin Dependent Diabetes Mellitus) [4]. 
Pancreatic endocrine cells, especially β-cells, 
play a vital role in the development of both the 
types of diabetes. In Type 1 diabetes, the body's 
immune system aberrantly destroys the insulin-
producing β-cells of the pancreas [5]. Type 2 
diabetes is characterized both by insulin 
resistance, a condition in which various tissues in 
the body become unresponsive to insulin action, 
and by decline in β-cell function to the point that 
the cells can no longer produce enough 
additional insulin to overcome the insulin 
resistance [6].   
 
It is possible to treat diabetes mellitus type 1 with 
islet transplantation [7]. Transplanted islet tissue 
more closely simulates the physiology of the lost 
islets, and patients no longer require multiple 
daily insulin injections. Current data revealed that 
72% recipient of islets transplantation became 
insulin-independent [8]. However, the limited 
supply of immune-compatible cadaver 
islets/pancreas is one of the barrier that made 
the islet transplantation unfeasible. Deriving β-
cells from stem cells presents an attractive and 
promising therapeutic option.  Stem cells, mainly 
the pluripotent stem cells, demonstrate strong 
self-renewal abilities and have the ability to 
differentiate into any cell types of the body, 
making them a chief source for regenerative 
medicine and tissue engineering [9,10]. This 
review is intended to shed light on the prospect 
of use of stem cells and its types as a viable 
option to treat diabetes in the near future.  
 
2. LIMITATIONS OF CONVENTIONAL 
DIABETES TREATMENT 
 
Glucose homeostasis depends upon insulin 
secretion by pancreatic β-cells [11]. In basal 
conditions, insulin secreted at the rate of 2 
pmol/kg/min [12] and after ingestion of meal this 
rate increases 5 – 10 fold [13]. Generally, human 
pancreas contains approximately one million 
islets, each containing approximately two 
thousand β-cells [14]. β-cells constitute 1-2 g of 
total pancreatic mass and 40% loss of the same 
can be tolerated without a significant 
deterioration of glucose tolerance [15]. But, 
further reduction in β-cell mass results in 
hyperglycemia. Once hyperglycemia develops 
90% of β-cells have been lost [16]. Therefore, β-
cell replacement is a potential therapy that might 
 
Table 1.The Incidence of diabetes in India 
 
1 Total adult population (20-79 years) (in 1000s) 798,988 
2 Prevalence of diabetes in adults (20-79 years) (%) 8.7 
3 Total cases of adults with diabetes (20-79 years) (in 1000s) 69,188.6 
4 Number of deaths in adults due to diabetes (20-79 years) 1,027,911 
5 Cost per person with diabetes (USD) 94.9 
6 Number of cases of diabetes in adults that are undiagnosed (1000s) - yearly basis 36,061.1 
Source: International Diabetes Federation (IDF), 2015 
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reverse the case. Pancreas transplantation is 
effective [17]. However, limited organ availability 
and the risks associated with relatively major 
surgery and life-long immune-suppression limits 
the use of this option [18]. Islet transplantation 
overcomes the need for major surgery but it does 
not overcome the limitation of organ availability 
and is much less successful than pancreas 
transplantation at accomplishing sustained 
insulin independence [19-21]. To overcome the 
shortage of available pancreas or islets for 
transplantation stem cells have been visualized 
as potential solution for the treatment of 
diabetes.  
 
3. NOVEL STRATEGIES OF TREATMENT- 
A STEM CELLS PERSPECTIVE 
 
Stem cells not only have the ability of self-
renewal but also can give rise to differentiated 
cells [22,23]. Because of its proliferation and 
differentiation capabilities, stem cells provide a 
great potential for the development of novel cell-
based therapies [24,25]. Type 1 diabetes might 
well be a suitable disease for stem cell therapy, 
as the causative damage is localized to a 
particular cell type. In theory, stem cells that can 
differentiate into β-cells in response to molecular 
signals in the local pancreatic environment could 
be introduced into the body, where they would 
migrate to the damaged tissue and differentiate 
as necessary to maintain the appropriate β-cell 
mass. As such, stem cell therapy would directly 
benefit persons with type 1diabetes by 
replenishing β-cells that are destroyed by 
autoimmune processes, although it would still be 
necessary to mitigate the autoimmune 
destruction of β-cells.  
 
4. CLASSIFICATION OF STEM CELLS  
 
According to Hongxiang Hui et al., Stem cells 
can be classified into 3 categories, namely: 
 
4.1 Embryonic Stem Cells 
 
Embryonic stem cells are pluripotent stem cells 
derived from the inner cell mass of the 
blastocyst, an early stage embryo. 
 
4.2 Adult Stem Cells  
 
4.2.1 Endodermal origin  
 
Pulmonary epithelial stem cells, gastrointestinal 
tract stem cells, pancreatic stem cells, hepatic 
oval cells, mammary and prostatic gland stem 
cells, ovarian and testicular stem cells. 
 
4.2.2 Mesodermal origin 
 
Haematopoietic stem cells, mesenchymal stroma 
stem cells, mesenchymal stem cells, 
mesenchymal precursor stem cells, multipotent 
adult progenitor cells, bone marrow stem cells, 
fetal somatic stem cells, unrestricted somatic 
stem cells, cardiac stem cells and satellite cells 
of muscle. 
 
4.2.3 Ectodermal origin 
 
Neural stem cells, skin stem cells and ocular 
stem cells. 
 
4.3 Induced Pluripotent Stem Cells 
 
A type of pluripotent stem cells artificially derives 
from a non-pluripotent cell, typically an adult 
somatic stem cells, by inducing a “forced” 
expression of specific genes. 
 
5. SOURCES OF STEM CELLS TO 
DERIVE PANCREATIC β-CELLS 
 
The main sources of stem cells, includes human 
embryonic stem cells (hESCs)/induced 
pluripotent stem cells (iPSCs), pancreatic 
stem/progenitor cells, and non-pancreatic stem 
cells. There is also evidence of adult β cells 
regeneration through β cell replication and 
cellular reprogramming [26]. 
 
6. FROM HUMAN EMBRYONIC STEM 
CELLS TO PANCREATIC β-CELLS 
 
Human Embryonic Stem cells (hESCs) are 
derived from the inner cell layer of the blastocyst 
[27,28] and have the ability to form cells derived 
from all three germ layers. These cells 
subsequently give rise to all differentiated cells in 
the adult though a series of cell fate choices that 
involve self-renewal and differentiation. A 
stepwise differentiation protocol is explored to 
derive functional pancreatic β cells from 
hESCs/iPSCs, by mimicking the signal used 
during embryonic pancreatic development. This 
involves directing ESCs first to form definitive 
endoderm, and then pancreatic progenitors 
followed by formation of endocrine progenitors, β 
cell precursors, and finally mature β cells. 
 
The primary step in the protocol is to derive the 
definitive endoderm from hESCs with Wingless-
type MMTV integration site family, member      
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3A (Wnt3a) and activin A treatment, expressing 
SOX17, a marker of definitive endoderm in ~70% 
cells. A chemical named Stauprimide, functions 
through sensitizing ESCs to a variety of 
differentiation signals and increase the number of 
endodermal cells in the presence of low levels of 
activin A [29]. After screening about 5000 
chemicals, two compounds, named IDE-1 and 
IDE-2, were identified to induce the differentiation 
of hESCs to definitive endoderm in the absence 
of Wnt3a and activin A, by activating alternate 
pathway called TGFβ signaling pathway [30].   
 
The next step in the protocol is differentiating 
definitive endoderm into pancreatic progenitors.  
Compound called Indolactam – V, identified to 
increase both number and percentage of 
pancreatic progenitors. The mechanism is 
through the activation of Protein Kinase C (PKC), 
although the most relevant PKC isoform has not 
been identified [31]. And also, Indolactam – V 
has been used to promote the generation of 
pancreatic progenitors from induced pluripotent 
stem cells (iPSCs) derived from type 1 Diabetes 
mellitus patients [32] and healthy human 
fibroblasts [33]. The current differentiation 
protocols produce a heterogeneous population, 
containing 50–80% Pdx1 cells. This 
heterogeneous Pdx 1 cell population is able to 
transform into glucose-responding cells and 
protects mice against streptozotocin-induced 
hyperglycemia in a SCID-Beige mice [34]. 
 
During embryonic pancreatic development, the 
pancreatic progenitors differentiate into 
endocrine, exocrine, and duct lineages [35].  
Endocrine development is solely maintained by 
the key regulators namely, bHLH protein 
Neurogenin 3 (Ngn3), which is expressed in 
endocrine precursors, but reduced during 
differentiation [36].  Delta – Notch and TGFβ 
signals are critical to endocrine development 
[37,38]. In addition, inhibiting the Bone 
Morphogenetic Protein (BMP) signaling pathway 
by using any chemical or proteins are increasing 
the probability of differentiating pancreatic 
progenitor towards endocrine progenitor [39], 
which subsequently increases the efficiency to 
make C- peptide + cells. C – peptide or 
connecting peptide, is a short 31 amino acid 
polypeptide that connects insulin A – chain to its 
B – chain in the proinsulin molecule. It is the by-
product of insulin biosynthesis, commonly used 
as a measurement of insulin gene expression 
[40].  
 
The next stage is the framing of endocrine 
progenitors into insulin-expressing β cell 
precursors. Glucagon-like peptide 1 (GLP-1) 
receptor signaling[41], insulin signaling [42], and 
PI3K/AKT signaling [43] are essential for the 
survival and proliferation of adult β cells. Despite 
that, little is known about the extrinsic signal that 
directs the endocrine progenitor’s differentiation 
to β cells during embryogenesis. Although 
different growth factors, including exendin 4 (a 
glucagon- like protein receptor agonist), DAPT (a 
g-secretase/Notch inhibitor), Hepatocyte Growth 
Factor (HGF), Insulin like Growth Factor-1 (IGF-
1) and Fibroblast Growth Factor (FGF), or 
nicotinamide [44,45], are revealed during the 
differentiation from Pdx1 + pancreatic 
progenitors to β cells, there is no strong 
confirmation to suggest the fruitfulness of these 
factors on hESC/iPSC differentiation. 
 
The final stage in the protocol is the maturation 
of β cells to acquire the activity of glucose-
stimulated insulin secretion (GSIS). To attain 
GSIS, β cell precursors need to develop the 
mechanism for glucose transport (such as 
GLUT2), glucose sensing (such as glucokinase), 
insulin processing, and exocytosis (such as 
PCSK1 and 2) [46,47]. Musculoaponeurotic 
fibrosarcoma oncogene homologue B and A 
(MafB and MafA) may partially come up with this 
activity during development or in response to 
glucose stimulation [48]. Recently, Blum et al. 
reported that increase in the glucose threshold 
results in functional β cell maturation with 
expression of urocortin3, a marker specifically 
expressed in mature β cells [49]. Currently, GSIS 
can be achieved only by in vivo implantation, and 
not by any in vitro differentiation protocol to a 
level similar to adult islets [50]. Therefore, the 
late stage β cell maturation process is still 
unknown and needs to be studied further. 
 
7. FROM INDUCED PLURIPOTENT STEM 
CELLS TO β-CELLS 
 
In 2006 & 2007, the Yamanaka group and the 
Thompson group came up with two different set 
of transcriptional factors such as Octamer 
binding transcription factor 4 (OCT4), Sex 
determining region Y box-2 (SOX2), Kruppel like 
factor 4 (KLF4) & Myc (cMYC) [51] and OCT4, 
SOX2, & Lin-28 homolog A (LIN28) [52] 
respectively, proved that adult cells can be 
transformed to a pluripotent stage. These cells, 
termed induced Pluripotent Stem Cells (iPSCs), 
have unlimited proliferation ability. Current 
studies on iPSCs revealed its applications in 
replacement therapy and disease modeling.  The 
process involves delivering pluripotency 
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associated set of transcription factors to any 
adult cell types which will reprogram the cell into 
a pluripoptent state in which it was 
transdifferentiated to become β cells.  
Reprogramming of cells can be done across cell 
lineage boundaries (eg. Fibroblast to β cells) 
[53]. By using the stepwise differentiation 
protocol, human iPSCc (hiPSCs) derived from 
both type1 diabetes patients and healthy controls 
become insulin-secreting cells [54]. Using a 
similar stepwise protocol, Tateishi et al. showed 
that hiPSCs derived from the healthy skin 
fibroblasts can be differentiated into c-peptide 
expressing cells under serum-free and feeder-
free conditions [55]. Another group used slightly 
different protocols to make glucose-responsive 
cells from skin fibroblast-derived iPSCs [56].  
Santamaria et al. used an embryoid body-based 
protocol to derive c-peptide expressing cells from 
keratinocytes. [57]. Alipio et al. segregated 
iPSCs-derived insulin-secreting cells from mouse 
skin fibroblasts and successfully inoculated these 
insulin secreting cells to ameliorate 
hyperglycemia in types 1 and 2 diabetes mouse 
models [58]. Moreover, an iPSC line from rhesus 
monkey was observed to have an insulin-
expressing nature through a stepwise process 
[59].  However, hESCs and iPSCs are derived 
using different approaches, and no systemic 
comparison of pancreatic differentiation 
potentials between hESCs and iPSCs has been 
performed yet. 
 
8. CHALLENGES IN DERIVING 
PANCREATIC β-CELLS FROM hESCs 
/ iPSCs 
 
In spite current successes in directing 
hESCs/iPSCs into insulin-secreting cells in vitro, 
still many hurdles are present that needs to be 
overcome to use hESC-derived cells at 
applicaiton level. Firstly, the insulin-secreting 
cells derived using current stepwise protocol 
often express multiple endocrine hormones, such 
as insulin and glucagon; therefore, these cells 
did not resemble mature pancreatic β-cells.  And 
also, the amount of insulin produced in 
hESC/iPSC-derived insulin secreting cells is 
much lower than adult β-cells. These insulin 
secreting cells do not respond to glucose 
stimulation in the same way as adult pancreatic 
β-cells [60]. Secondly, the undifferentiated cells 
in the hESC/hiPSC-derived heterogenous 
population might form teratomas after 
transplantation.  Even though signals for 
differentiating hESCs/iPSCs into pancreatic cells 
are there, but 100% efficiency is questionable.  
On the other hand, teratoma forming cells may 
be removed from heterogeneously differentiated 
cells by immunodepletion with antibody against 
stage specific embryonic antigen-5 (SSEA-5) 
[61]. Thirdly, retroviral or lentiviral systems are 
used in differentiating iPSCs into insulin-
expressing cells, which cause genetic mutation 
resulting in detrimental outcome. Recently, RNA 
delivery and protein transduction overcome those 
limitations by providing excisable virus free 
delivery of reprogramming factors [62-66], but 
need to be validated in cells of diabetes patients.  
Lastly, the microenvironment, i.e. vasculatures 
needed to support grafted islets cells.  
Vasculature niches provide an environment for 
insulin expression and β-cell proliferation [67,68]. 
Vascularization ensures not only nutrients and 
oxygen supply but also the intact functions of β-
cells, and achieved by enhanced expression of 
Vascular Endothelial Growth Factor (VEGF) or 
co-transplant with mesenchymal stem cells 
(MSCs) [69-71]. On other hand, extracellular 
matrix components and 3-D scaffolds have been 
proved to facilitate the proliferation, survival, and 
insulin secretion of islets or purified β-cells 
[72,73]. To conclude, the microenvironment of 
grafted islets needs to be studied carefully to 
increase the success rate of stem cell therapy. 
 
9. OTHER STEM CELL SOURCES TO 
DERIVE PANCREATIC β-CELLS 
 
9.1 Adult Pancreatic Stem Cells 
 
The major source for β-cell neogenesis is by the 
differentiation and proliferation of pancreatic duct 
cells using the pancreatic duct ligation model of 
injury [74]. Duct cells expressing carbonic 
anhydrase II could act as progenitors that give 
rise to both new islets and acinar cells after birth 
or after ductal ligation injury [75]. Efficient 
strategies need to be established to isolate and 
expand the adult pancreatic stem/ progenitor 
cells into β-cells. Pancreatic duct epithelial cells 
were isolated and induced in vitro to become 
function islets that responded to glucose 
challenge and reversed insulin - dependent 
diabetes [76]. Seaberg et al. reported the 
multiple precursor cells from adult mouse 
pancreas are clonally identical. Upon 
differentiation, individual identical colonies 
produced distinct populations of endocrine, 
exocrine cells, as well as neurons and glia.  The 
β-like cells showed glucose-dependent 
responsiveness and insulin release [77]. Suzuki 
et al. described pancreatic stem cells, which are 
able to differentiate into pancreatic endocrine 
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and exocrine cells following transplantation using 
perspective isolation and clonal analysis [78].  
Most of the current studies on adult pancreatic 
stem/progenitor cells are still at the proof of 
principle stage of manipulating endogenous adult 
pancreatic stem/progenitor cells into β-cell 
lineage. 
 
9.2 Adult non-pancreatic stem cells 
 
Adult tissue stem cells like HSCs and MSCs 
have the ability to transdifferentiate damage 
tissues and dead cells. Highly proliferative HSCs 
obtained from adult bone marrow undergo well-
established purification methods before 
transplantation protocols to treat haemodynamic 
disorders. After autologous HSC transplantation 
in a patient diagnosed with type 1 diabetes 
mellitus, Couri et al. noticed increase in blood c-
peptide levels and insulin independence [79]. 
Zhang et al. also showed that islet function in 
type 1 diabetes patients improves after HSC 
transplantation, but the mechanism behind that is 
the elimination of the islet specific autoreactive T 
cells but not transdifferentiation into β-cells. In 
addition, many recent studies reports that after 
transplantation, HSCs have a minor role in 
insulin secretion, but plays a major role in 
stimulating the proliferation of existing β-cells 
and facilitate survival of the same [80-84].  
Therefore, the ability of HSCs to directly 
differentiate into pancreatic β-cells after 
transplantation is still controversial. Ianus et al. 
showed that the ability of bone marrow-derived 
cells to differentiate into pancreatic endocrine β-
cells with predicted cell markers and glucose-
dependent insulin secretion activity [85]. Another 
group also showed the ability of bone marrow-
derived MSCs to transdifferentiate into insulin-
secreting cells under defined conditions in vitro 
and to ameliorate hyperglycemia after 
transplantation [86]. Later, other groups found 
that after autologous transplantation, MSCs 
maintains a microenvironment to support existing 
β-cells survival and activity, produces 
normoglycemia [87,88]. Therefore, MSCs play 
supportive roles to restore hyperglycemia in 
diabetic animals and differentiation to pancreatic 
β-cells remains to be documented.   
 
10. FROM SOMATIC CELLS TO 
PANCREATIC β-CELLS 
 
10.1 Replication of β-cells 
 
β-cells have a very low proliferating capacity, but 
in response to physiological changes adult β-
cells gets stimulated and proliferate to maintain 
its mass. Nir et al. found replication of existing β-
cells had a vital role in regeneration of pancreatic 
β-cells in a diabetic mouse model [89]. The β-cell 
mass is dynamic and balanced by β-cell 
formation and β-cell apoptosis. Certain 
physiological states like pregnancy [90], obesity 
and in cases of insulin resistance [91] human 
pancreatic β-cells can able to proliferate. Growth 
hormones, placental lactogen, prolactin, GLP-1, 
and glucose showed to stimulate β-cell 
population to replicate in a rodent islet model 
[92]. Attempts at expanding human islets ex vivo 
are being done to obtain β-cells for replacement 
therapy [93]. A number of structurally diverse 
molecule were identified that promote β-cell 
replication, including novel Wnt signaling 
agonists and L-type calcium channel agonists 
[94].   
 
10.2 Reprogramming of Pancreatic 
Lineage 
 
Pancreatic exocrine cells, duct cells, and other 
endocrine cells share development resemblance 
with β-cells other than somatic cells. Ngn3, Pdx1, 
and MafA, is essential for β-cell function, which 
reprogram mouse exocrine cells similar to β-cells 
in vivo. The induced β-cells can ameliorate 
hyperglycemia by reconstructing local 
vasculature and secreting insulin [95]. In 
addition, epidermal growth factor (EGF) and 
leukemia inhibitory factor (LIF) transdifferentiate 
rat exocrine cells into β-cells at low efficiency in 
vitro. After transplantation, these exocrine-
derived β-cells restored normoglycemia [96].  
Lineage tracing results showed that EGF 
signaling can transdifferentiate mouse pancreatic 
acinar cells into insulin-secreting cells with 
similar property to those of native pancreatic β-
cells.  Developmental transcriptional factor NGN3 
helps in reprogramming the duct cells isolated 
from adult human pancreas to islet β-cell genes 
by adenoviral [97]. 
 
Endocrine reprogramming of α-cells to β-cells 
can be induced by β-cell loss and exogenous 
gene expression. Pancreatic cell plasticity 
confirms large fraction of β-cells derives from 
glucagon producing α-cells after β-cell removal 
[98]. Pancreatic and duodenal homeobox 1 
(Pdx1) could induce context-dependent α-cells 
reprogramming to β-cells [99]. 
 
10.3 Reprogramming from Other Adult 
Cells 
 
Adult hepatocytes and pancreas share foregut 
endoderm, which can be successfully 
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reprogrammed into β-like cells.  In 2000, Ferber 
and Karasik et al. reported that hepatocytes are 
able to express active insulin with Pdx1 gene and 
to alleviate hyperglycemia in diabetic mice 
treated with streptozotocin. The protein encoded 
by Pdx1 gene plays a central role in regulating 
pancreas development and islet cell function 
[100]. In 2005, the same group engineered adult 
human liver cells to c-peptide secreting cells in 
response to glucose concentration and rescue 
hyperglycemia in a rodent model, by introducing 
ectopic Pdx1 and supplementing EGF and 
nicotinamide [101]. The efficiency of 
reprogramming can be improved by the addition 
of exendin-4 and NKS6.1 genes [102,103].  
Other groups used NeuroDand or Ngn3 together 
with the Pdx1 gene to reprogram rodent livers in 
vivo to insulin producing cells, which corrected 
hyperglycemia in diabetic animals [104,105].  In 
addition to hepatocytes, ectopic Pdx1 expression 
reprograms keratinocytes to insulin-expressing 
cells [106]. 
 
11. CONCLUSION 
 
The treatment of diabetes with stem cell therapy 
seems to have lot of scope and the ability of 
stem cells derived from different sources have 
shown promising potencies to differentiate into β 
cells, though the exact mechanisms of stem cell 
differentiation into target cells is to be unraveled. 
Considerable advancements have been made in 
the conversion of non-islet cells into islet 
hormone secreting cells with main aim of 
providing insulin secretion, and ideally glucose 
responsiveness, for the control of diabetes.  The 
production of pure β cell populations from ESC, 
progenitor cells, or iPSCs may prove sufficient to 
restore glucose homeostasis. Apart from the 
differentiation of stem cells to islet cells in vitro, 
the major challenge in their use for diabetes is 
going to be the understanding of mechanisms 
involved in homing of differentiated cells.  
 
12. FUTURE PROSPECT 
 
In recent years, stem cell biology has been 
advancing at an extremely rapid speed and 
evidence is accumulating that shows the 
enormous potential of stem cell technology, 
which might hold the answer to cure some 
devastating disease such as diabetes. Since the 
iPSCs have given the option of deriving stem 
cells from the affected individuals without the use 
of embryos, the major challenge of ethical issues 
involved in stem cell therapy is also addressed. 
With respect to treatment of diabetes, unfurling 
the further details related to efficient stem cell 
differentiation to B cells without possible 
complications will brighten the prospect of stem 
cell therapy.  
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